The MPTP-lesioned non-human primate models of Parkinson's disease. Past, present, and future

Progress in Brain Research

Volumn 184, Issue C, 2010, Pages 133-157

  Fox, Susan H ^a,b   Brotchie, Jonathan M ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY HEALTH NETWORK   (Canada)

Author keywords

MPTP; Non human primate; Non motor; Parkinson's disease

Indexed keywords

1 (1 CYCLOOCTYLMETHYL 3 HYDROXYMETHYL 4 PIPERIDYL) 3 ETHYL 1,3 DIHYDRO 2H BENZIMIDAZOL 2 ONE; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 3 ETHYNYL 5 (1 METHYL 2 PYRROLIDINYL)PYRIDINE; 4 BENZYL ALPHA (4 HYDROXYPHENYL) BETA METHYL 1 PIPERIDINEPROPANOL; AMANTADINE; BIPERIDEN; CLOZAPINE; CYPRODIME; DECAHYDRO 6 PHOSPHONOMETHYL 3 ISOQUINOLINECARBOXYLIC ACID; DIZOCILPINE; ENADOLINE; FIPAMEZOLE; IDAZOXAN; IFENPRODIL; ISTRADEFYLLINE; LEVODOPA; METHYSERGIDE; NABILONE; NALOXONE; NALTREXONE; PIMAVANSERIN; PRAZOSIN; QUETIAPINE; RIMONABANT; SARIZOTAN; TALAMPANEL; TRAXOPRODIL; TRIHEXYPHENIDYL; UNINDEXED DRUG; YOHIMBINE;

BOOK; COGNITIVE DEFECT; DISEASE COURSE; DISEASE MODEL; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG POTENTIATION; DYSTONIA; HUMAN; MOTOR DYSFUNCTION; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PARKINSONISM; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; SLEEP DISORDER;

EID: 77955402231     PISSN: 00796123     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S0079-6123(10)84007-5     Document Type: Chapter

References (207)

1. Akai T., Ozawa M., Yamaguchi M., Mizuta E., Kuno S. Combination treatment of the partial D2 agonist terguride with the D1 agonist SKF 82958 in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned parkinsonian cynomolgus monkeys. Journal of Pharmacology and Experimental Therapeutics 1995, 273:309-314.
2. Alexander G.M., Schwartzman R.J., Brainard L., Gordon S.W., Grothusen J.R. Changes in brain catecholamines and dopamine uptake sites at different stages of MPTP parkinsonism in monkeys. Brain Research 1992, 588:261-269.
3. Annett L.E., Torres E.M., Ridley R.M., Baker H.F., Dunnett S.B. A comparison of the behavioural effects of embryonic nigral grafts in the caudate nucleus and in the putamen of marmosets with unilateral 6-OHDA lesions. Experimental Brain Research 1995, 103:355-371.
4. Apicella P., Trouche E., Nieoullon A., Legallet E., Dusticier N. Motor impairments and neurochemical changes after unilateral 6-hydroxydopamine lesion of the nigrostriatal dopaminergic system in monkeys. Neuroscience 1990, 38:655-666.
5. Aziz T.Z., Peggs D., Sambrook M.A., Crossman A.R. Lesion of the subthalamic nucleus for the alleviation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the primate. Movement Disorder 1991, 6:288-292.
6. Bankiewicz K.S., Oldfield E.H., Chiueh C.C., Doppman J.L., Jacobowitz D.M., Kopin I.J. Hemiparkinsonism in monkeys after unilateral internal carotid artery infusion of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Life Sciences 1986, 39:7-16.
7. Barcia C., Bautista V., Sanchez-Bahillo A., Fernandez-Villalba E., Navarro-Ruis J.M., Barreiro A.F., et al. Circadian determinations of cortisol, prolactin and melatonin in chronic methyl-phenyl-tetrahydropyridine-treated monkeys. Neuroendocrinology 2003, 78:118-128.
8. Barraud Q., Lambrecq V., Forni C., McGuire S., Hill M., Bioulac B., et al. Sleep disorders in Parkinson's disease: The contribution of the MPTP non-human primate model. Experimental Neurology 2009, 219:574-582.
9. Belzunegui S., San Sebastian W., Garrido-Gil P., Izal-Azcarate A., Vazquez-Claverie M., Lopez B., et al. The number of dopaminergic cells is increased in the olfactory bulb of monkeys chronically exposed to MPTP. Synapse 2007, 61:1006-1012.
10. Bergman H., Raz A., Feingold A., Nini A., Nelken I., Hansel D., et al. Movement Disorder 1998, 13(Suppl 3):29-34.
11. Bergman H., Wichmann T., DeLong M.R. Reversal of experimental parkinsonism by lesions of the subthalamic nucleus. Science 1990, 249:1436-1438.
12. Bezard E. A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. Behavioural Pharmacology 2006, 17:379-382.
13. Bezard E., Brefel C., Tison F., Peyro-Saint-Paul H., Ladure P., Rascol O., et al. Effect of the alpha 2 adrenoreceptor antagonist, idazoxan, on motor disabilities in MPTP-treated monkey. Progress in Neuro-Psychopharmacology and Biological Psychiatry 1999, 23:1237-1246.
14. Bezard E., Dovero S., Prunier C., Ravenscroft P., Chalon S., Guilloteau D., et al. Relationship between the appearance of symptoms and the level of nigrostriatal degeneration in a progressive 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaque model of Parkinson's disease. Journal of Neuroscience 2001, 21:6853-6861.
15. Bezard E., Imbert C., Deloire X., Bioulac B., Gross C.E. A chronic MPTP model reproducing the slow evolution of Parkinson's disease: Evolution of motor symptoms in the monkey. Brain Research 1997, 766:107-112.
16. Bezard E., Ravenscroft P., Gross C.E., Crossman A.R., Brotchie J.M. Upregulation of striatal preproenkephalin gene expression occurs before the appearance of parkinsonian signs in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine monkeys. Neurobiology of Disease 2001, 8:343-350.
17. Bibbiani F., Oh J.D., Chase T.N. Serotonin 5-HT1A agonist improves motor complications in rodent and primate parkinsonian models. Neurology 2001, 57:1829-1834.
18. Bibbiani F., Oh J.D., Kielaite A., Collins M.A., Smith C., Chase T.N. Combined blockade of AMPA and NMDA glutamate receptors reduces levodopa-induced motor complications in animal models of PD. Experimental Neurology 2005, 196:422-429.
19. Bibbiani F., Oh J.D., Petzer J.P., Castagnoli N., Jr., Chen J.F., Schwarzschild M.A., et al. A2A antagonist prevents dopamine agonist-induced motor complications in animal models of Parkinson's disease. Experimental Neurology 2003, 184:285-294.
20. Blanchet P.J., Konitsiotis S., Chase T.N. Amantadine reduces levodopa-induced dyskinesias in parkinsonian monkeys. Movement Disorder 1998, 13:798-802.
21. Blanchet P.J., Konitsiotis S., Whittemore E.R., Zhou Z.L., Woodward R.M., Chase T.N. Differing effects of N-methyl-D-aspartate receptor subtype selective antagonists on dyskinesias in levodopa-treated 1-methyl-4-phenyl-tetrahydropyridine monkeys. Journal of Pharmacology and Experimental Therapeutics 1999, 290:1034-1040.
22. * nAChRs in mouse, monkey, and Parkinson's disease striatum. Molecular Pharmacology 2007, 72:52-61.
23. Boyce S., Clarke C.E., Luquin R., Peggs D., Robertson R.G., Mitchell I.J., et al. Induction of chorea and dystonia in parkinsonian primates. Movement Disorder 1990, 5:3-7.
24. Boyce S., Rupniak N.M., Steventon M.J., Iversen S.D. Characterisation of dyskinesias induced by L-dopa in MPTP-treated squirrel monkeys. Psychopharmacology (Berlin) 1990, 102:21-27.
25. Braak H., Del Tredici K., Rub U., de Vos R.A., Jansen Steur E.N., Braak E. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging 2003, 24:197-211.
26. Brotchie J.M. Nondopaminergic mechanisms in levodopa-induced dyskinesia. Movement Disorder 2005, 20:919-931.
27. Brotchie J.M., Fox S.H. Quantitative assessment of dyskinesias in subhuman primates. Movement Disorder 1999, 14(Suppl 1):40-47.
28. Burns R.S., Chiueh C.C., Markey S.P., Ebert M.H., Jacobowitz D.M., Kopin I.J. A primate model of parkinsonism: Selective destruction of dopaminergic neurons in the pars compacta of the substantia nigra by N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Proceedings of the National Academy of Sciences of the United States of America 1983, 80:4546-4550.
29. Calon F., Morissette M., Ghribi O., Goulet M., Grondin R., Blanchet P.J., et al. Alteration of glutamate receptors in the striatum of dyskinetic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated monkeys following dopamine agonist treatment. Progress in Neuro-Psychopharmacology and Biological Psychiatry 2002, 26:127-138.
30. Campos-Romo A., Ojeda-Flores R., Moreno-Briseno P., Fernandez-Ruiz J. Quantitative evaluation of MPTP-treated nonhuman parkinsonian primates in the HALLWAY task. Journal of Neuroscience Methods 2009, 177:361-368.
31. Cao X., Liang L., Hadcock J.R., Iredale P.A., Griffith D.A., Menniti F.S., et al. Blockade of cannabinoid type 1 receptors augments the antiparkinsonian action of levodopa without affecting dyskinesias in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated rhesus monkeys. Journal of Pharmacology and Experimental Therapeutics 2007, 323:318-326.
32. Chaumette T., Lebouvier T., Aubert P., Lardeux B., Qin C., Li Q., et al. Neurochemical plasticity in the enteric nervous system of a primate animal model of experimental Parkinsonism. Neurogastroenterol Motility 2009, 21:215-222.
33. Chen M.K., Kuwabara H., Zhou Y., Adams R.J., Brasic J.R., McGlothan J.L., et al. VMAT2 and dopamine neuron loss in a primate model of Parkinson's disease. Journal of Neurochemistry 2008, 105:78-90.
34. Chen L., Togasaki D.M., Langston J.W., Di Monte D.A., Quik M. Enhanced striatal opioid receptor-mediated G-protein activation in L-DOPA-treated dyskinetic monkeys. Neuroscience 2005, 132:409-420.
35. Chiba K., Trevor A., Castagnoli N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochemical and Biophysical Research Communications 1984, 120:574-578.
36. Chu Y., Kordower J.H. Age-associated increases of alpha-synuclein in monkeys and humans are associated with nigrostriatal dopamine depletion: Is this the target for Parkinson's disease?. Neurobiology of Disease 2007, 25:134-149.
37. Clarke C.E., Sambrook M.A., Mitchell I.J., Crossman A.R. Levodopa-induced dyskinesia and response fluctuations in primates rendered parkinsonian with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Journal of the Neurological Sciences 1987, 78:273-280.
38. Collantes M., Penuelas I., Alvarez-Erviti L., Blesa J., Marti-Climent J.M., Quincoces G., et al. Use of 11C-(+)-alpha-dihydrotetrabenazine for the assessment of dopaminergic innervation in animal models of Parkinson's disease]. Revista Española de Medicina Nuclear 2008, 27:103-111.
39. Collier T.J., Lipton J., Daley B.F., Palfi S., Chu Y., Sortwell C., et al. Aging-related changes in the nigrostriatal dopamine system and the response to MPTP in nonhuman primates: Diminished compensatory mechanisms as a prelude to parkinsonism. Neurobiology of Disease 2007, 26:56-65.
40. Cox H., Togasaki D.M., Chen L., Langston J.W., Di Monte D.A., Quik M. The selective kappa-opioid receptor agonist U50,488 reduces L-dopa-induced dyskinesias but worsens parkinsonism in MPTP-treated primates. Experimental Neurology 2007, 205:101-107.
41. Crossman A.R., Mitchell I.J., Sambrook M.A. Regional brain uptake of 2-deoxyglucose in N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-induced parkinsonism in the macaque monkey. Neuropharmacology 1985, 24:587-591.
42. Decamp E., Schneider J.S. Interaction between nicotinic and dopaminergic therapies on cognition in a chronic Parkinson model. Brain Research 2009, 1262:109-114.
43. DeLong M.R., Crutcher M.D., Georgopoulos A.P. Primate globus pallidus and subthalamic nucleus: Functional organization. Journal of Neurophysiology 1985, 53:530-543.
44. Di Marzo V., Hill M.P., Bisogno T., Crossman A.R., Brotchie J.M. Enhanced levels of endogenous cannabinoids in the globus pallidus are associated with a reduction in movement in an animal model of Parkinson's disease. Federation of American Societies for Experimental Biology Journal 2000, 14:1432-1438.
45. Domino E.F., Ni L. Trihexyphenidyl potentiation of L-DOPA: Reduced effectiveness three years later in MPTP-induced chronic hemiparkinsonian monkeys. Experimental Neurology 1998, 152:238-242.
46. Domino E.F., Ni L. Biperiden enhances L-DOPA methyl ester and dopamine D(l) receptor agonist SKF-82958 but antagonizes D(2)/D(3) receptor agonist rotigotine antihemiparkinsonian actions. European Journal of Pharmacology 2008, 599:81-85.
47. Domino E.F., Ni L., Colpaert F., Marien M. Effects of (+/-)-idazoxan alone and in combination with L-DOPA methyl ester in MPTP-induced hemiparkinsonian monkeys. Receptors Channels 2003, 9:335-338.
48. Doudet D.J., Rosa-Neto P., Munk O.L., Ruth T.J., Jivan S., Cumming P. Effect of age on markers for monoaminergic neurons of normal and MPTP-lesioned rhesus monkeys: A multi-tracer PET study. Neuroimage 2006, 30:26-35.
49. Emborg M.E. Nonhuman primate models of Parkinson's disease. Ilar Journal 2007, 48:339-355.
50. Emborg M.E., Moirano J., Schafernak K.T., Moirano M., Evans M., Konecny T., et al. Basal ganglia lesions after MPTP administration in rhesus monkeys. Neurobiology of Disease 2006, 23:281-289.
51. Eslamboli A. Marmoset monkey models of Parkinson's disease: Which model, when and why?. Brain Research Bulletin 2005, 68:140-149.
52. Eslamboli A., Baker H.F., Ridley R.M., Annett L.E. Sensorimotor deficits in a unilateral intrastriatal 6-OHDA partial lesion model of Parkinson's disease in marmoset monkeys. Experimental Neurology 2003, 183:418-429.
53. Eslamboli A., Romero-Ramos M., Burger C., Bjorklund T., Muzyczka N., Mandel R.J., et al. Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain 2007, 130:799-815.
54. Everett G.M., Blockus L.E., Shepperd I.M. Tremor induced by tremorine and its antagonism by anti-Parkinson drugs. Science 1956, 124:79.
55. Forno L.S., Langston J.W., DeLanney L.E., Irwin I., Ricaurte G.A. Locus ceruleus lesions and eosinophilic inclusions in MPTP-treated monkeys. Annals of Neurology 1986, 20:449-455.
56. Fox S.H., Henry B., Hill M., Crossman A., Brotchie J. Stimulation of cannabinoid receptors reduces levodopa-induced dyskinesia in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorder 2002, 17:1180-1187.
57. Fox S.H., Henry B., Hill M.P., Peggs D., Crossman A.R., Brotchie J.M. Neural mechanisms underlying peak-dose dyskinesia induced by levodopa and apomorphine are distinct: Evidence from the effects of the alpha(2) adrenoceptor antagonist idazoxan. Movement Disorder 2001, 16:642-650.
58. Fox S.H., Koprich J.B., Johnston T.H., Goodman B., Le Bourdonnec B., Dolle R.E., et al. Mu-selective but not non-selective opiod receptor antagonism reduces L-DOPA-induced dyskinesia in the MPTP macaque model of Parkinson's disease. Mov disord 2010, 25(suppl):412.
59. Fox S.H., Lang A.E., Brotchie J.M. Translation of nondopaminergic treatments for levodopa-induced dyskinesia from MPTP-lesioned nonhuman primates to phase IIa clinical studies: Keys to success and roads to failure. Movement Disorder 2006, 21:1578-1594.
60. Fox S.H., Visanji N.P., Johnston T.H., Gomez-Ramirez J., Voon V., Brotchie J.M. Dopamine receptor agonists and levodopa and inducing psychosis-like behavior in the MPTP primate model of Parkinson disease. Archives of Neurology 2006, 63:1343-1344.
61. Fox S.H., Visanji N.P., Reyes G., Huot P., Gomez-Ramirez J., Johnston T.H., et al. Development of psychosis-like behaviors and motor complications with de novo levodopa treatment in the MPTP primate model of Parkinson's disease. Canadian Journal of Neurological Sciences 2010, 37:86-95.
62. Garcia, B. G., Neely, M. D., & Deutch, A. Y. (2010). Cortical regulation of striatal medium spiny neuron dendritic remodeling in parkinsonism: modulation of glutamate release reverses dopamine depletion-induced dendritic spine loss. Cerebral Cortex. Jan 29 (epub ahead of print).
63. Garrido-Gil P., Belzunegui S., San Sebastian W., Izal-Azcarate A., Lopez B., Marcilla I., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine exposure fails to produce delayed degeneration of substantia nigra neurons in monkeys. Journal of Neuroscience Research 2009, 87:586-597.
64. Gaspar P., Febvret A., Colombo J. Serotonergic sprouting in primate MTP-induced hemiparkinsonism. Experimental Brain Research 1993, 96:100-106.
65. Gibb W.R., Lees A.J., Wells F.R., Barnard R.O., Jenner P., Marsden C.D. Pathology of MPTP in the marmoset. Advanced Neurology 1987, 45:187-190.
66. Goetz C.G., Damier P., Hicking C., Laska E., Muller T., Olanow C.W., et al. Sarizotan as a treatment for dyskinesias in Parkinson's disease: A double-blind placebo-controlled trial. Movement Disorder 2007, 22:179-186.
67. Goetz C.G., Tilley B.C., Shaftman S.R., Stebbins G.T., Fahn S., Martinez-Martin P., et al. Movement disorder society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Scale presentation and clinimetric testing results. Movement Disorder 2008, 23:2129-2170.
68. Goldstein D.S., Li S.T., Holmes C., Bankiewicz K. Sympathetic innervation in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine primate model of Parkinson's disease. Journal of Pharmacology and Experimental Therapeutics 2003, 306:855-860.
69. Gomez-Mancilla B., Bedard P.J. Effect of nondopaminergic drugs on L-dopa-induced dyskinesias in MPTP-treated monkeys. Clinical Neuropharmacology 1993, 16:418-427.
70. Gomez-Ramirez J., Johnston T.H., Visanji N.P., Fox S.H., Brotchie J.M. Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorder 2006, 21:839-846.
71. Gregoire L., Samadi P., Graham J., Bedard P.J., Bartoszyk G.D., Di Paolo T. Low doses of sarizotan reduce dyskinesias and maintain antiparkinsonian efficacy of L-Dopa in parkinsonian monkeys. Parkinsonism and Related Disorders 2009, 15:445-452.
72. Griffiths P.D., Sambrook M.A., Perry R., Crossman A.R. Changes in benzodiazepine and acetylcholine receptors in the globus pallidus in Parkinson's disease. Journal of the Neurological Sciences 1990, 100:131-136.
73. Grondin R., Bedard P.J., Hadj Tahar A., Gregoire L., Mori A., Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology 1999, 52:1673-1677.
74. Grondin R., Doan V.D., Gregoire L., Bedard P.J. D1 receptor blockade improves L-dopa-induced dyskinesia but worsens parkinsonism in MPTP monkeys. Neurology 1999, 52:771-776.
75. Guigoni C., Dovero S., Aubert I., Li Q., Bioulac B.H., Bloch B., et al. Levodopa-induced dyskinesia in MPTP-treated macaques is not dependent on the extent and pattern of nigrostrial lesioning. European Journal of Neuroscience 2005, 22:283-287.
76. Hadj Tahar A., Gregoire L., Darre A., Belanger N., Meltzer L., Bedard P.J. Effect of a selective glutamate antagonist on L-dopa-induced dyskinesias in drug-naive parkinsonian monkeys. Neurobiology of Disease 2004, 15:171-176.
77. Hallett P.J., Brotchie J.M. Striatal delta opioid receptor binding in experimental models of Parkinson's disease and dyskinesia. Movement Disorder 2007, 22:28-40.
78. Hallett P.J., Dunah A.W., Ravenscroft P., Zhou S., Bezard E., Crossman A.R., et al. Alterations of striatal NMDA receptor subunits associated with the development of dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Neuropharmacology 2005, 48:503-516.
79. Halliday G., Herrero M.T., Murphy K., McCann H., Ros-Bernal F., Barcia C., et al. No Lewy pathology in monkeys with over 10 years of severe MPTP parkinsonism. Movement Disorder 2009, 24:1519-1523.
80. Hantraye P., Varastet M., Peschanski M., Riche D., Cesaro P., Willer J.C., et al. Stable parkinsonian syndrome and uneven loss of striatal dopamine fibres following chronic MPTP administration in baboons. Neuroscience 1993, 53:169-178.
81. Hardy J. Expression of normal sequence pathogenic proteins for neurodegenerative disease contributes to disease risk: "Permissive templating" as a general mechanism underlying neurodegeneration. Biochemical Society Transactions 2005, 33:578-581.
82. Hauser R.A., Friedlander J., Zesiewicz T.A., Adler C.H., Seeberger L.C., O'Brien C.F., et al. A home diary to assess functional status in patients with Parkinson's disease with motor fluctuations and dyskinesia. Clinical Neuropharmacology 2000, 23:75-81.
83. Hely M.A., Reid W.G., Adena M.A., Halliday G.M., Morris J.G. The Sydney multicenter study of Parkinson's disease: The inevitability of dementia at 20 years. Movement Disorder 2008, 23:837-844.
84. Henry B., Fox S.H., Crossman A.R., Brotchie J.M. Mu- and delta-opioid receptor antagonists reduce levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Experimental Neurology 2001, 171:139-146.
85. Henry B., Fox S.H., Peggs D., Crossman A.R., Brotchie J.M. The alpha2-adrenergic receptor antagonist idazoxan reduces dyskinesia and enhances anti-parkinsonian actions of L-dopa in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorder 1999, 14:744-753.
86. Herrero M.T., Augood S.J., Hirsch E.C., Javoy-Agid F., Luquin M.R., Agid Y., et al. Effects of L-DOPA on preproenkephalin and preprotachykinin gene expression in the MPTP-treated monkey striatum. Neuroscience 1995, 68:1189-1198.
87. Hill M.P., Brotchie J.M. Modulation of glutamate release by a kappa-opioid receptor agonist in rodent and primate striatum. European Journal of Pharmacology 1995, 281:R1-R2.
88. Hughes A.J., Daniel S.E., Kilford L., Lees A.J. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: A clinico-pathological study of 100 cases. Journal of Neurology, Neurosurgery and Psychiatry 1992, 55:181-184.
89. Huot, P. H., Johnston, T. H., Brotchie, J. M., & Fox, S. H. (2010). Abnormal 5-HT2A-mediated neurotransmission in dyskinetic MPTP-lesioned macaques. Neurobiology of Aging. Jan 17 (Epub ahead of print).
90. Huot, P. H., Johnston, T. H., Winkelmolen, L., Fox, S. H., & Brotchie, J. M. (in submission-b). 5-HT1A receptors in dyskinetic and non-dyskinetic MPTP-lesioned macaques.
91. Hurley M.J., Jackson M.J., Smith L.A., Rose S., Jenner P. Immunoautoradiographic analysis of NMDA receptor subunits and associated postsynaptic density proteins in the brain of dyskinetic MPTP-treated common marmosets. European Journal of Neuroscience 2005, 21:3240-3250.
92. Imbert C., Bezard E., Guitraud S., Boraud T., Gross C.E. Comparison of eight clinical rating scales used for the assessment of MPTP-induced parkinsonism in the Macaque monkey. Journal of Neuroscience Methods 2000, 96:71-76.
93. Inazu M., Takeda H., Matsumiya T. Expression and functional characterization of the extraneuronal monoamine transporter in normal human astrocytes. Journal of Neurochemistry 2003, 84:43-52.
94. Iravani M.M., Syed E., Jackson M.J., Johnston L.C., Smith L.A., Jenner P. A modified MPTP treatment regime produces reproducible partial nigrostriatal lesions in common marmosets. European Journal of Neuroscience 2005, 21:841-854.
95. Iravani M.M., Tayarani-Binazir K., Chu W.B., Jackson M.J., Jenner P. In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability. Journal of Pharmacology and Experimental Therapeutics 2006, 319:1225-1234.
96. Jackson M.J., Al-Barghouthy G., Pearce R.K., Smith L., Hagan J.J., Jenner P. Effect of 5-HT1B/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets. Pharmacology Biochemistry and Behavior 2004, 79:391-400.
97. Javitch J.A., D'Amato R.J., Strittmatter S.M., Snyder S.H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: Uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective toxicity. Proceedings of the National Academy of Sciences of the United States of America 1985, 82:2173-2177.
98. Jenner P. The contribution of the MPTP-treated primate model to the development of new treatment strategies for Parkinson's disease. Parkinsonism and Related Disorders 2003, 9:131-137.
99. Jenner P. The MPTP-treated primate as a model of motor complications in PD: Primate model of motor complications. Neurology 2003, 61:S4-S11.
100. Jenner P., Rupniak N.M., Rose S., Kelly E., Kilpatrick G., Lees A., et al. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the common marmoset. Neuroscience Letters 1984, 50:85-90.
101. Johnston T.H., Fox S.H., McIldowie M.J., Piggott M.J., Brotchie J.M. M. Reduction of L-DOPA-induced dyskinesia by the selective metabotropic glutamate receptor 5 (mGlu5) antagonist MTEP in the MPTP-lesioned macaque model of Parkinson's disease. J Pharmacol Exp Ther 2010, 333:865-873.
102. Johnston, T. H., van der meij, A., Brotchie, J. M., Fox, S. H. (2010) The histamine H2 receptor antagonist famotidine enhances the anti-parkinsonian actions afforded by L-DOPA in the MPTP-lesioned macaque. Movement Disorder in press. Mar 22 (Epub ahead of print).
103. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., et al. Adenosine A2A antagonist: A novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Annals of Neurology 1998, 43:507-513.
104. Kanda T., Jackson M.J., Smith L.A., Pearce R.K., Nakamura J., Kase H., et al. Combined use of the adenosine A(2A) antagonist KW-6002 with L-DOPA or with selective D1 or D2 dopamine agonists increases antiparkinsonian activity but not dyskinesia in MPTP-treated monkeys. Experimental Neurology 2000, 162:321-327.
105. Kirik D., Bjorklund A. Modeling CNS neurodegeneration by overexpression of disease-causing proteins using viral vectors. Trends in Neurosciences 2003, 26:386-392.
106. Kitayama S., Wang J.B., Uhl G.R. Dopamine transporter mutants selectively enhance MPP+ transport. Synapse 1993, 15:58-62.
107. Klintenberg R., Svenningsson P., Gunne L., Andren P.E. Naloxone reduces levodopa-induced dyskinesias and apomorphine-induced rotations in primate models of parkinsonism. Journal of Neural Transmission 2002, 109:1295-1307.
108. Konitsiotis S., Blanchet P.J., Verhagen L., Lamers E., Chase T.N. AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 2000, 54:1589-1595.
109. Kordower J.H., Chu Y., Hauser R.A., Freeman T.B., Olanow C.W. Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease. Nature Medicine 2008, 14:504-506.
110. Kordower J.H., Emborg M.E., Bloch J., Ma S.Y., Chu Y., Leventhal L., et al. Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson's disease. Science 2000, 290:767-773.
111. Kowall N.W., Hantraye P., Brouillet E., Beal M.F., McKee A.C., Ferrante R.J. MPTP induces alpha-synuclein aggregation in the substantia nigra of baboons. Neuroreport 2000, 11:211-213.
112. * nicotinic acetylcholine receptor expression changes with progressive parkinsonism in non-human primates. Neurobiology of Disease 2007, 27:312-319.
113. Kulak J.M., McIntosh J.M., Quik M. Loss of nicotinic receptors in monkey striatum after 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine treatment is due to a decline in alpha-conotoxin MII sites. Molecular Pharmacology 2002, 61:230-238.
114. Kulisevsky J., Pagonabarraga J. Cognitive impairment in Parkinson's disease: Tools for diagnosis and assessment. Movement Disorder 2009, 24:1103-1110.
115. Kuoppamaki M., Al-Barghouthy G., Jackson M., Smith L., Zeng B.Y., Quinn N., et al. Beginning-of-dose and rebound worsening in MPTP-treated common marmosets treated with levodopa. Movement Disorder 2002, 17:1312-1317.
116. Lang A.E., Gill S., Patel N.K., Lozano A., Nutt J.G., Penn R., et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Annals of Neurology 2006, 59:459-466.
117. Langston J.W., Ballard P.A. Parkinson's disease in a chemist working with 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine. New England Journal of Medicine 1983, 309:310.
118. Langston J.W., Langston E.B., Irwin I. MPTP-induced parkinsonism in human and non-human primates - clinical and experimental aspects. Acta Neurologica Scandinavica Supplementum 1984, 100:49-54.
119. Lastres-Becker I., Cebeira M., de Ceballos M.L., Zeng B.Y., Jenner P., Ramos J.A., et al. Increased cannabinoid CB1 receptor binding and activation of GTP-binding proteins in the basal ganglia of patients with Parkinson's syndrome and of MPTP-treated marmosets. European Journal of Neuroscience 2001, 14:1827-1832.
120. Li W., Lesuisse C., Xu Y., Troncoso J.C., Price D.L., Lee M.K. Stabilization of alpha-synuclein protein with aging and familial parkinson's disease-linked A53T mutation. Journal of Neuroscience 2004, 24:7400-7409.
121. Lim S.Y., Fox S.H., Lang A.E. Overview of the extranigral aspects of Parkinson disease. Archives of Neurology 2009, 66:167-172.
122. Liu N., Yue F., Tang W.P., Chan P. An objective measurement of locomotion behavior for hemiparkinsonian cynomolgus monkeys. Journal of Neuroscience Methods 2009, 183:188-194.
123. Loschmann P.A., De Groote C., Smith L., Wullner U., Fischer G., Kemp J.A., et al. Antiparkinsonian activity of Ro 25-6981, a NR2B subunit specific NMDA receptor antagonist, in animal models of Parkinson's disease. Experimental Neurology 2004, 187:86-93.
124. Mamikonyan E., Moberg P.J., Siderowf A., Duda J.E., Have T.T., Hurtig H.I., et al. Mild cognitive impairment is common in Parkinson's disease patients with normal Mini-Mental State Examination (MMSE) scores. Parkinsonism and Related Disorders 2009, 15:226-231.
125. Maneuf Y.P., Mitchell I.J., Crossman A.R., Woodruff G.N., Brotchie J.M. Functional implications of kappa opioid receptor-mediated modulation of glutamate transmission in the output regions of the basal ganglia in rodent and primate models of Parkinson's disease. Brain Research 1995, 683:102-108.
126. Manson A.J., Iakovidou E., Lees A.J. Idazoxan is ineffective for levodopa-induced dyskinesias in Parkinson's disease. Movement Disorder 2000, 15:336-337.
127. McCormack A.L., Mak S.K., Shenasa M., Langston W.J., Forno L.S., Di Monte D.A. Pathologic modifications of alpha-synuclein in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-treated squirrel monkeys. Journal of Neuropathology and Experimental Neurology 2008, 67:793-802.
128. Meissner W., Prunier C., Guilloteau D., Chalon S., Gross C.E., Bezard E. Time-course of nigrostriatal degeneration in a progressive MPTP-lesioned macaque model of Parkinson's disease. Molecular Neurobiology 2003, 28:209-218.
129. Mera T.O., Johnson M.D., Rothe D., Zhang J., Xu W., Ghosh D., et al. Objective quantification of arm rigidity in MPTP-treated primates. Journal of Neuroscience Methods 2009, 177:20-29.
130. Meschler J.P., Howlett A.C., Madras B.K. Cannabinoid receptor agonist and antagonist effects on motor function in normal and 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP)-treated non-human primates. Psychopharmacology (Berlin) 2001, 156:79-85.
131. Mestre T.J.T., Brotchie J.M., Fox S. Evolution of the "short duration" response to L-DOPA in the MPTP-lesioned non-human primate model of Parkinson's disease. Movement Disorder 2010, 417.
132. Mihara T., Iwashita A., Matsuoka N. A novel adenosine A(1) and A(2A) receptor antagonist ASP5854 ameliorates motor impairment in MPTP-treated marmosets: Comparison with existing anti-Parkinson's disease drugs. Behavioural Brain Research 2008, 194:152-161.
133. Miller G.W., Erickson J.D., Perez J.T., Penland S.N., Mash D.C., Rye D.B., et al. Immunochemical analysis of vesicular monoamine transporter (VMAT2) protein in Parkinson's disease. Experimental Neurology 1999, 156:138-148.
134. Mitchell I.J., Cross A.J., Sambrook M.A., Crossman A.R. Sites of the neurotoxic action of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in the macaque monkey include the ventral tegmental area and the locus coeruleus. Neuroscience Letters 1985, 61:195-200.
135. Mitchell I.J., Hughes N., Carroll C.B., Brotchie J.M. Reversal of parkinsonian symptoms by intrastriatal and systemic manipulations of excitatory amino acid and dopamine transmission in the bilateral 6-OHDA lesioned marmoset. Behavioural Pharmacology 1995, 6:492-507.
136. Miwa T., Watanabe A., Mitsumoto Y., Furukawa M., Fukushima N., Moriizumi T. Olfactory impairment and Parkinson's disease-like symptoms observed in the common marmoset following administration of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Acta Otolaryngology Supplement 2004, 553:80-84.
137. Morin N., Gregoire L., Gomez-Mancilla B., Gasparini F., et al. Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys. Neuropharmacology 2010, 58:981-986.
138. Morissette M., Dridi M., Calon F., Hadj Tahar A., Meltzer L.T., Bedard P.J., et al. Prevention of dyskinesia by an NMDA receptor antagonist in MPTP monkeys: Effect on adenosine A2A receptors. Synapse 2006, 60:239-250.
139. Morissette M., Goulet M., Soghomonian J.J., Blanchet P.J., Calon F., Bedard P.J., et al. Preproenkephalin mRNA expression in the caudate-putamen of MPTP monkeys after chronic treatment with the D2 agonist U91356A in continuous or intermittent mode of administration: Comparison with L-DOPA therapy. Brain Research Molecular Brain Research 1997, 49:55-62.
140. Mounayar S., Boulet S., Tande D., Jan C., Pessiglione M., Hirsch E.C., et al. A new model to study compensatory mechanisms in MPTP-treated monkeys exhibiting recovery. Brain 2007, 130:2898-2914.
141. Nagai Y., Obayashi S., Ando K., Inaji M., Maeda J., Okauchi T., et al. Progressive changes of pre- and post-synaptic dopaminergic biomarkers in conscious MPTP-treated cynomolgus monkeys measured by positron emission tomography. Synapse 2007, 61:809-819.
142. Nandi D., Jenkinson N., Stein J., Aziz T. The pedunculopontine nucleus in Parkinson's disease: Primate studies. British Journal of Neurosurgery 2008, 22(Suppl 1):S4-S8.
143. Nash J.E., Brotchie J.M. A common signaling pathway for striatal NMDA and adenosine A2a receptors: Implications for the treatment of Parkinson's disease. Journal of Neuroscience 2000, 20:7782-7789.
144. Nash J.E., Ravenscroft P., McGuire S., Crossman A.R., Menniti F.S., Brotchie J.M. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease. Experimental Neurology 2004, 188:471-479.
145. Nutt J.G., Carter J.H., Lea E.S., Sexton G.J. Evolution of the response to levodopa during the first 4 years of therapy. Annals of Neurology 2002, 51:686-693.
146. Obeso J.A., Rodriguez-Oroz M.C., Rodriguez M., DeLong M.R., Olanow C.W. Pathophysiology of levodopa-induced dyskinesias in Parkinson's disease: Problems with the current model. Annals of Neurology 2000, 47:S22-S32. discussion S32-S34.
147. Oh J.D., Bibbiani F., Chase T.N. Quetiapine attenuates levodopa-induced motor complications in rodent and primate parkinsonian models. Experimental Neurology 2002, 177:557-564.
148. Olanow C.W., Rascol O., Hauser R., Feigin P.D., Jankovic J., Lang A., et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease. New England Journal of Medicine 2009, 361:1268-1278.
149. Ouattara B., Belkhir S., Morissette M., Dridi M., Samadi P., Gregoire L., et al. Implication of NMDA receptors in the antidyskinetic activity of cabergoline, CI-1041, and Ro 61-8048 in MPTP monkeys with levodopa-induced dyskinesias. Journal of Molecular Neuroscience 2009, 38:128-142.
150. Ouattara B., Gasparini F., Morissette M., Gregoire L., Samadi P., Gomez-Mancilla B., et al. Effect of L-Dopa on metabotropic glutamate receptor 5 in the brain of parkinsonian monkeys. Journal of Neurochemistry 2010, 113:715-724.
151. Ovadia A., Zhang Z., Gash D.M. Increased susceptibility to MPTP toxicity in middle-aged rhesus monkeys. Neurobiology of Aging 1995, 16:931-937.
152. Pahwa R., Factor S.A., Lyons K.E., Ondo W.G., Gronseth G., Bronte-Stewart H., et al. Practice Parameter: Treatment of Parkinson disease with motor fluctuations and dyskinesia (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006, 66:983-995.
153. Papa S.M., Chase T.N. Levodopa-induced dyskinesias improved by a glutamate antagonist in Parkinsonian monkeys. Annals of Neurology 1996, 39:574-578.
154. Pearce R.K.B., Banerji T., Jackson M., Jenner P., Marsden C.D. Cholinergic manipulation of L-DOPA-induced chorea and dystonia in the MPTP-lesioned common marmoset. Movement disorders 1999, 11(Suppl. 1):60.
155. Pearce R.K., Jackson M., Smith L., Jenner P., Marsden C.D. Chronic L-DOPA administration induces dyskinesias in the 1-methyl-4- phenyl-1,2,3,6-tetrahydropyridine-treated common marmoset (Callithrix jacchus). Movement Disorder 1995, 10:731-740.
156. Pechadre J.C., Larochelle L., Poirier L.J. Parkinsonian akinesia, rigidity and tremor in the monkey. Histopathological and neuropharmacological study. Journal of the Neurological Sciences 1976, 28:147-157.
157. Perez-Otano I., Herrero M.T., Oset C., De Ceballos M.L., Luquin M.R., Obeso J.A., et al. Extensive loss of brain dopamine and serotonin induced by chronic administration of MPTP in the marmoset. Brain Research 1991, 567:127-132.
158. Perez-Otano I., Oset C., Luquin M.R., Herrero M.T., Obeso J.A., Del Rio J. MPTP-induced parkinsonism in primates: Pattern of striatal dopamine loss following acute and chronic administration. Neuroscience Letters 1994, 175:121-125.
159. Pertwee R.G., Wickens A.P. Enhancement by chlordiazepoxide of catalepsy induced in rats by intravenous or intrapallidal injections of enantiomeric cannabinoids. Neuropharmacology 1991, 30:237-244.
160. Pessiglione M., Guehl D., Jan C., Francois C., Hirsch E.C., Feger J., et al. Disruption of self-organized actions in monkeys with progressive MPTP-induced parkinsonism: II. Effects of reward preference. European Journal of Neuroscience 2004, 19:437-446.
161. Pifl C., Schingnitz G., Hornykiewicz O. Effect of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine on the regional distribution of brain monoamines in the rhesus monkey. Neuroscience 1991, 44:591-605.
162. Poirier L.J. Experimental and histological study of midbrain dyskinesias. Journal of Neurophysiology 1960, 23:534-551.
163. Poirier L.J., Langelier P., Bedard P., Boucher R., Larochelle L., Parent A., et al. Dopaminergic and cholinergic mechanisms in relation to postural tremor in the monkey and circling movements in the cat. Advanced Neurology 1974, 5:5-10.
164. Postuma R.B., Gagnon J.F., Vendette M., Fantini M.L., Massicotte-Marquez J., Montplaisir J. Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder. Neurology 2009, 72:1296-1300.
165. Przedborski S., Jackson-Lewis V., Djaldetti R., Liberatore G., Vila M., Vukosavic S., et al. The parkinsonian toxin MPTP: Action and mechanism. Restorative Neurology and Neuroscience 2000, 16:135-142.
166. Przedborski S., Jackson-Lewis V., Naini A.B., Jakowec M., Petzinger G., Miller R., et al. The parkinsonian toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP): A technical review of its utility and safety. Journal of Neurochemistry 2001, 76:1265-1274.
167. DATATOP: A multicenter controlled clinical trial in early Parkinson's disease. Parkinson Study Group. Archives of Neurology 1989, 46:1052-1060. PSG.
168. Purisai M.G., McCormack A.L., Langston W.J., Johnston L.C., Di Monte D.A. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates. Neurobiology of Disease 2005, 20:898-906.
169. Quik M., Cox H., Parameswaran N., O'Leary K., Langston J.W., Di Monte D. Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys. Annals of Neurology 2007, 62:588-596.
170. Quik M., Police S., Langston J.W., Di Monte D.A. Increases in striatal preproenkephalin gene expression are associated with nigrostriatal damage but not L-DOPA-induced dyskinesias in the squirrel monkey. Neuroscience 2002, 113:213-220.
171. Quinn N.P. Classification of fluctuations in patients with Parkinson's disease. Neurology 1998, 51:S25-S29.
172. Ramsay R.R., Salach J.I., Dadgar J., Singer T.P. Inhibition of mitochondrial NADH dehydrogenase by pyridine derivatives and its possible relation to experimental and idiopathic parkinsonism. Biochemical and Biophysical Research Communications 1986, 135:269-275.
173. Rolland A.S., Tande D., Herrero M.T., Luquin M.R., Vazquez-Claverie M., Karachi C., et al. Evidence for a dopaminergic innervation of the pedunculopontine nucleus in monkeys, and its drastic reduction after MPTP intoxication. Journal of Neurochemistry 2009, 110:1321-1329.
174. Rose S., Jackson M.J., Smith L.A., Stockwell K., Johnson L., Carminati P., et al. The novel adenosine A2a receptor antagonist ST1535 potentiates the effects of a threshold dose of L-DOPA in MPTP treated common marmosets. European Journal of Pharmacology 2006, 546:82-87.
175. Rose S., Nomoto M., Jenner P., Marsden C.D. Transient depletion of nucleus accumbens dopamine content may contribute to initial akinesia induced by MPTP in common marmosets. Biochemical Pharmacology 1989, 38:3677-3681.
176. Rupniak N.M., Boyce S., Steventon M.J., Iversen S.D., Marsden C.D. Dystonia induced by combined treatment with L-dopa and MK-801 in parkinsonian monkeys. Annals of Neurology 1992, 32:103-105.
177. Russ H., Mihatsch W., Gerlach M., Riederer P., Przuntek H. Neurochemical and behavioural features induced by chronic low dose treatment with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) in the common marmoset: Implications for Parkinson's disease?. Neuroscience Letters 1991, 123:115-118.
178. Samadi P., Gregoire L., Bedard P.J. Opioid antagonists increase the dyskinetic response to dopaminergic agents in parkinsonian monkeys: Interaction between dopamine and opioid systems. Neuropharmacology 2003, 45:954-963.
179. Samadi P., Gregoire L., Morissette M., Calon F., Hadj Tahar A., Belanger N., et al. Basal ganglia group II metabotropic glutamate receptors specific binding in non-human primate model of L-Dopa-induced dyskinesias. Neuropharmacology 2008, 54:258-268.
180. Sanchez-Pernaute R., Wang J.Q., Kuruppu D., Cao L., Tueckmantel W., Kozikowski A., et al. Enhanced binding of metabotropic glutamate receptor type 5 (mGluR5) PET tracers in the brain of parkinsonian primates. Neuroimage 2008, 42:248-251.
181. Savola J.M., Hill M., Engstrom M., Merivuori H., Wurster S., McGuire S.G., et al. Fipamezole (JP-1730) is a potent alpha2 adrenergic receptor antagonist that reduces levodopa-induced dyskinesia in the MPTP-lesioned primate model of Parkinson's disease. Movement Disorder 2003, 18:872-883.
182. Schneider J.S., Gonczi H., Decamp E. Development of levodopa-induced dyskinesias in parkinsonian monkeys may depend upon rate of symptom onset and/or duration of symptoms. Brain Research 2003, 990:38-44.
183. Schneider J.S., Kovelowski C.J. Chronic exposure to low doses of MPTP. I. Cognitive deficits in motor asymptomatic monkeys. Brain Research 1990, 519:122-128.
184. Schneider J.S., Pope-Coleman A., Van Velson M., Menzaghi F., Lloyd G.K. Effects of SIB-1508Y, a novel neuronal nicotinic acetylcholine receptor agonist, on motor behavior in parkinsonian monkeys. Movement Disorder 1998, 13:637-642.
185. Silverdale M.A., Crossman A.R., Brotchie J.M. Striatal AMPA receptor binding is unaltered in the MPTP-lesioned macaque model of Parkinson's disease and dyskinesia. Experimental Neurology 2002, 174:21-28.
186. Slovin H., Abeles M., Vaadia E., Haalman I., Prut Y., Bergman H. Frontal cognitive impairments and saccadic deficits in low-dose MPTP-treated monkeys. Journal of Neurophysiology 1999, 81:858-874.
187. Smith L.A., Jackson M.J., Hansard M.J., Maratos E., Jenner P. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naive MPTP-treated common marmosets: Effect of dose, frequency of administration, and brain exposure. Movement Disorder 2003, 18:487-495.
188. Steece-Collier K., Chambers L.K., Jaw-Tsai S.S., Menniti F.S., Greenamyre J.T. Antiparkinsonian actions of CP-101,606, an antagonist of NR2B subunit-containing N-methyl-D-aspartate receptors. Experimental Neurology 2000, 163:239-243.
189. Tabbal S.D., Mink J.W., Antenor J.A., Carl J.L., Moerlein S.M., Perlmutter J.S. 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced acute transient dystonia in monkeys associated with low striatal dopamine. Neuroscience 2006, 141:1281-1287.
190. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond D.E. Cognitive and motor deficits in the acquisition of an object retrieval/detour task in MPTP-treated monkeys. Brain 1990, 113(Pt 3):617-637.
191. Taylor J.R., Elsworth J.D., Roth R.H., Sladek J.R., Redmond D.E. Severe long-term 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-induced parkinsonism in the vervet monkey (Cercopithecus aethiops sabaeus). Neuroscience 1997, 81:745-755.
192. Todd R.D., Carl J., Harmon S., O'Malley K.L., Perlmutter J.S. Dynamic changes in striatal dopamine D2 and D3 receptor protein and mRNA in response to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) denervation in baboons. Journal of Neuroscience 1996, 16:7776-7782.
193. Togasaki D.M., Hsu A., Samant M., Farzan B., DeLanney L.E., Langston J.W., et al. The Webcam system: A simple, automated, computer-based video system for quantitative measurement of movement in nonhuman primates. Journal of Neuroscience Methods 2005, 145:159-166.
194. Ungerstedt U. 6-hydroxydopamine-induced degeneration of the nigrostriatal dopamine pathway: The turning syndrome. Pharmacology and Therapeutics B 1976, 2:37-40.
195. van der Stelt M., Fox S.H., Hill M., Crossman A.R., Petrosino S., Di Marzo V., et al. A role for endocannabinoids in the generation of parkinsonism and levodopa-induced dyskinesia in MPTP-lesioned non-human primate models of Parkinson's disease. Federation of American Societies for Experimental Biology Journal 2005, 19:1140-1142.
196. Vanover K.E., Veinbergs I., Davis R.E. Antipsychotic-like behavioral effects and cognitive enhancement by a potent and selective muscarinic M-sub-1 receptor agonist, AC-260584. Behavioral Neuroscience 2008, 122:570-575.
197. Vazquez-Claverie M., Garrido-Gil P., San Sebastian W., Izal-Azcarate A., Belzunegui S., Marcilla I., et al. Acute and chronic 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine administrations elicit similar microglial activation in the substantia nigra of monkeys. Journal of Neuropathology and Experimental Neurology 2009, 68:977-984.
198. Verhave P.S., Vanwersch R.A., van Helden H.P., Smit A.B., Philippens I.H. Two new test methods to quantify motor deficits in a marmoset model for Parkinson's disease. Behavioural Brain Research 2009, 200:214-219.
199. Viaro R., Sanchez-Pernaute R., Marti M., Trapella C., Isacson O., Morari M. Nociceptin/orphanin FQ receptor blockade attenuates MPTP-induced parkinsonism. Neurobiology of Disease 2008, 30:430-438.
200. Villalba R.M., Lee H., Smith Y. Dopaminergic denervation and spine loss in the striatum of MPTP-treated monkeys. Experimental Neurology 2009, 215:220-227.
201. Visanji N.P., de Bie R.M., Johnston T.H., McCreary A.C., Brotchie J.M., Fox S.H. The nociceptin/orphanin FQ (NOP) receptor antagonist J-113397 enhances the effects of levodopa in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorder 2008, 23:1922-1925.
202. Visanji N.P., Fox S.H., Johnston T.H., Millan M.J., Brotchie J.M. Alpha1-adrenoceptors mediate dihydroxyphenylalanine-induced activity in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-lesioned macaques. Journal of Pharmacology and Experimental Therapeutics 2009, 328:276-283.
203. Visanji N.P., Fox S.H., Johnston T., Reyes G., Millan M.J., Brotchie J.M. Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiology of Disease 2009, 35:184-192.
204. Visanji N.P., Gomez-Ramirez J., Johnston T.H., Pires D., Voon V., Brotchie J.M., et al. Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorder 2006, 21:1879-1891.
205. Voon V., Fox S.H. Medication-related impulse control and repetitive behaviors in Parkinson disease. Archives of Neurology 2007, 64:1089-1096.
206. Voon V., Hassan K., Zurowski M., Duff-Canning S., de Souza M., Fox S., et al. Prospective prevalence of pathologic gambling and medication association in Parkinson disease. Neurology 2006, 66:1750-1752.
207. Westlund K.N., Denney R.M., Kochersperger L.M., Rose R.M., Abell C.W. Distinct monoamine oxidase A and B populations in primate brain. Science 1985, 230:181-183.